Equillium (EQ) Revenue & Revenue Breakdown
Equillium Revenue Highlights
Latest Revenue (Y)
$36.08M
Latest Revenue (Q)
$13.85M
Equillium Revenue by Period
Equillium Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $36.08M | 128.97% |
| 2022-12-31 | $15.76M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Equillium generated $36.08M in revenue during NA 2023, up 128.97% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Equillium Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $13.85M | 29.60% |
| 2024-03-31 | $10.69M | 16.05% |
| 2023-12-31 | $9.21M | 3.84% |
| 2023-09-30 | $8.87M | -2.78% |
| 2023-06-30 | $9.12M | 2.76% |
| 2023-03-31 | $8.88M | -43.66% |
| 2022-12-31 | $15.76M | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | - |
Equillium generated $13.85M in revenue during Q2 2024, up 29.60% compared to the previous quarter, and up 156.02% compared to the same period a year ago.
Equillium Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CHRS | Coherus BioSciences | $257.24M | $64.98M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| EQ | Equillium | $36.08M | $13.85M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| IKNA | Ikena Oncology | $9.16M | - |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| CUE | Cue Biopharma | $5.49M | $1.72M |
| SABS | SAB Biotherapeutics | $2.24M | $263.14K |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| LIAN | LianBio | - | - |
| ANTX | AN2 Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| BCAB | BioAtla | - | - |
| TRVI | Trevi Therapeutics | - | - |
| CVKD | Cadrenal Therapeutics | - | - |
| NLTX | Neurogene | - | - |
| MNPR | Monopar Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
| JSPR | Jasper Therapeutics | - | - |
| KTTA | Pasithea Therapeutics | - | - |
EQ Revenue FAQ
What is Equillium’s yearly revenue?
Equillium's yearly revenue for 2023 was $36.08M, representing an increase of 128.97% compared to 2022. The company's yearly revenue for 2022 was $15.76M, representing an increase of 100.00% compared to 2021. EQ's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Equillium’s quarterly revenue?
Equillium's quarterly revenue for Q2 2024 was $13.85M, a 29.60% increase from the previous quarter (Q1 2024), and a 51.83% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $10.69M, a 16.05% increase from the previous quarter (Q4 2023), and a 20.39% increase year-over-year (Q1 2023). EQ's quarterly revenue for Q4 2023 was $9.21M, a 3.84% increase from the previous quarter (Q3 2023), and a -41.55% decrease year-over-year (Q4 2022).
What is Equillium’s revenue growth rate?
Equillium's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.